← All trials
NCT00958633
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2010
- Primary completion
- Mar 31, 2019
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 216
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of British ColumbiaLead sponsor
- University of British ColumbiaOverall official - principal investigator
- Asha Hospital, Hyderabad, IndiaStudy director
- McGill UniversityStudy director
- Kasturba Medical CollegeStudy director
- Seoul National UniversityStudy director
- University of TorontoStudy director
- University of Western OntarioStudy director
- University of UlsanStudy director
- GlaxoSmithKlineCollaborator
- LundbeckCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- Kyungpook UniversityStudy director
- National Institute of Mental Health and Neuro Sciences, IndiaStudy director
- Queen's University, BelfastStudy director
- Rajiv Gandhi University of Health SciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.